この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2024/7/221 分で読めます
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME; Correction
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 2, 2024. The document announced the determination of the regulatory review period for XENPOZYME (olipudase alfa-rpcp) for purposes of patent extension. The document was published with an incorrect patent number. This notice corrects the patent number.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →